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Glioblastoma (GB) is the most malignant of primary adult brain tumors, characterized by
a highly locally invasive cell population, as well as abundant proliferative cells, neoangio-
genesis, and necrosis. Clinical intervention with chemotherapy or radiation may either
promote or establish an environment for manifestation of invasive behavior. Understand-
ing the molecular drivers of invasion in the context of glioma progression may be insightful
in directing new treatments for patients with GB. Here, we review current knowledge on
Rho family GTPases, their aberrant regulation in GB, and their effect on GB cell invasion and
tumor progression. Rho GTPases are modulators of cell migration through effects on actin
cytoskeleton rearrangement; in non-neoplastic tissue, expression and activation of Rho
GTPases are normally under tight regulation. In GB, Rho GTPases are deregulated, often
via hyperactivity or overexpression of their activators, Rho GEFs. Downstream effectors of
Rho GTPases have been shown to promote invasiveness and, importantly, glioma cell sur-
vival. The study of aberrant Rho GTPase signaling in GB is thus an important investigation
of cell invasion as well as treatment resistance and disease progression.
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GLIOMA CHARACTERIZATION
Gliomas comprise the most common group of primary brain
tumors and are of neuroepithelial designation, named for a glial
cell origin (1). These tumors include astrocytomas, oligoden-
drogliomas, and ependymomas, with infiltrating astrocytomas
accounting for approximately 80% of adult primary brain tumors
(2). Within each glial cell lineage, tumors are divided into grades
based on their biologic behavior across one of four grades of
increasing aggressiveness (grade I to grade IV); grading confers
some prognostic guidance as well as informs treatment proto-
cols. Clinically, glioblastoma (GB) (grade IV) represents the most
malignant primary brain tumors, for which there is no cure (2).
Glioblastoma tumors arise in two scenarios: primary GB with
new onset disease, or secondary GB with a previous history of
lower grade astrocytoma. Gliomas rarely metastasize outside the
CNS (2), but can be highly invasive within the brain parenchyma.
Both lower grade as well as high-grade tumors display marked
invasiveness, suggesting this malignant phenotype may be
acquired early in tumorigenesis (3). Gliomas preferentially invade
along white-matter tracts of the cerebrum, at times crossing the
corpus callosum. Other patterns of cell spreading include perivas-
cular growth, subpial spread, or perineuronal satellitosis (3).
The 5-year survival rate for GB is under 10% (4). Unfortunately,
prognosis for GB patients has not significantly changed over the
past several decades despite increased molecular understanding of
the tumor. The problem of resistance to standard anti-proliferative
Abbreviations: GAP, GTPase-activating protein; GB, glioblastoma; GDI, guanine
nucleotide dissociation inhibitor; GEF, guanine nucleotide exchange factor.
treatment with concomitant radiotherapy and chemotherapy
using the alkylating agent temozolomide (TMZ) is common, par-
ticularly manifest by the invasive cell population with subsequent
tumor recurrence and death. The role of pro-invasive genes in GB
progression remains understudied and the link between cell inva-
sion and therapeutic insensitivity remains poorly characterized.
Notably, treatments directed at impairing mediators of invasion
have been shown to increase chemotherapeutic sensitivity (5–7).
Glioma cell invasion is promoted via the overexpression of
receptors such as MET or EGFR, as well as downstream signal-
ing through PI3K and MAPK pathways, and the Rho family of
GTPases, among others (8, 9). This increased invasive potential
arises from overexpression or mutation of drivers of cell motility,
from interactions of glioma cells with pro-migratory signals within
the brain tumor microenvironment, but also, notably, as a response
to treatment (10). The Rho family of small GTPases, including pri-
marily Rac1, Cdc42, and RhoG are key signaling mediators of GB
cell invasion. Members of this signaling family as well as their
regulators and effectors represent novel molecular targets against
which therapeutic intervention could be aimed, and the implica-
tions for their signaling deregulation in gliomas is the subject of
this review.
Rho GTPase FUNCTION AND REGULATION
The Rho family of GTPases belongs to the Ras superfamily;
they are monomeric low molecular weight proteins. There are
20 known mammalian Rho protein members, divided in part
into subfamilies including Rho, Rac, Cdc42, Rnd, RhoD, RhoF,
RhoH, and RhoBTB (11–16). Rho GTPases exist in either an
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inactive GDP-bound state, or an active GTP-bound state dur-
ing which the GTPase can interact with downstream effectors.
Switching between the inactive and active conformations is medi-
ated by three classes of proteins: Guanine nucleotide exchange
factors (GEFs), GTPase-activating proteins (GAPs), and Rho
GDIs. GEFs are responsible for GTP loading. Stimulation of
Rho GTPase intrinsic GTP-to-GDP hydrolysis by GAPs facili-
tates Rho GTPase inactivation (17). Rho GTPases undergo post-
translational prenylation modifications, which are attached to the
carboxyl-terminal cysteine residue of the protein, allowing for
interactions with, and attachment at, phospholipid membranes
where Rho GTPases are activated and interact with signaling com-
plexes (18, 19). A third category of Rho GTPase family regulators
are the guanine nucleotide dissociation inhibitors (Rho GDIs)
which sequester Rho GTPases in their inactive conformation in
the cytosol by shielding the hydrophobic tail (20). Rho GTPase
activity can be regulated by nucleotide binding and subcellular
localization (21). Recent studies have also shown Rho GTPase
regulation via ubiquitin-proteasome degradation (22), as well as
the importance of Rho GDIs in controlling the homeostasis of
Rho proteins potentially by preventing protein degradation (23)
(Figure 1).
RhoA, Rac, and Cdc42 are well-characterized members of the
Rho family of GTPases and have been described as key regula-
tors of cell migration (17). RhoA was first described to promote
the assembly of contractile actomyosin filaments, or stress fibers,
and Rac promoted the assembly of a peripheral actin meshwork,
including lamellipodia (17,24,25). In addition to inducing periph-
eral actin rich microspikes, or filopodia, Cdc42 has been described
to activate Rac, demonstrating the existence of cross-talk within
the Rho family of GTPases (17, 26). Furthermore, RhoA and
Rac1 have been shown to mutually inhibit each other in some
studies, while other reports postulate a positive feedback (27).
Another Rho GTPase family member, RhoG, has been shown
to act upstream of Rac1 to stimulate cell movement, but also
signals to promote the robust formation of Rac1-independent
lamellipodia (28–31).
During the process of cell migration, actin-driven protrusions
at the leading edge of cell motility are driven by Rac activa-
tion, whereas actomyosin contractility at the cell body and rear
are coordinated by active Rho (32), with Cdc42 regulating cell
polarity through integrating extracellular directional cues (33,
34). Rac and Cdc42 share an overlapping set of downstream
effectors to enact cytoskeletal changes. Signaling via Pak and
MAPK activation, or via PI5K, Formin, or IQGAP leads to actin
reorganization downstream of either Rac or Cdc42. In addi-
tion, Cdc42 further signals via WASP and Rac further signals
via WAVE to enact cytoskeletal rearrangement (35). RhoG, which
has been described to signal both in concert with or in parallel
to Rac1 and Cdc42 also shares downstream effectors IQGAP2,
MLK3, and PLD1 with Rac1 and Cdc42, but confers indepen-
dent signaling as well (31). RhoA signaling leads to phospho-
rylation of myosin light chain (MLC) and is conferred by sev-
eral downstream effectors including the serine/threonine kinase
p160 ROCK (36–38). ROCK activity leads to increased MLC
phosphorylation via the inhibition of MLC phosphatase as well
as direct MLC phosphorylation (36, 38, 39). ROCK, together
FIGURE 1 | Regulation of Rho GTPases. Rho GTPase family members are
active in their GTP-bound state, mediated by guanine nucleotide exchange
factor (GEF) loading of GTP. GTPase-activating proteins (GAPs) catalyze
intrinsic Rho GTPase GTP-to-GDP hydrolysis, including the removal of
phosphate and the subsequent inactivation of the Rho GTPase. Guanine
nucleotide dissociation inhibitors (GDIs) sequester Rho GTPases in their
inactive GDP-bound conformation by shielding their hydrophobic tail.
Membrane interaction and attachment is important for Rho GTPase
activation and the promotion of subsequent downstream effector binding.
with the RhoA effector mDia, coordinates stress fiber formation
(38, 40).
While these signaling pathways are well-characterized, the
understanding of Rho GTPase regulation of cell movement has
become more complex. Tumor cell motility has been character-
ized to occur not only in a mesenchymal pattern with a spindle
like shape and an obvious leading cell edge, but also in an amoe-
boid fashion with cycles of expansion and contraction of the cell
body, potentially dependent upon the environment through which
the cells move (41, 42). Moreover, biosensors capable of visualiz-
ing active Rho family members have implicated that both Rho and
Rac can be active at leading edge protrusions (43). Thus the envi-
ronmental regulation and spatiotemporal control of Rho GTPases
are key factors in the regulation of cytoskeletal dynamics toward
cell locomotion.
The activity of Rho GTPases is tightly regulated. Rho GEFs
belong either to the Dbl or Dock families. Dbl proteins con-
tain a Dbl homology (DH) domain responsible for catalyzing
the exchange of GDP for GTP (12); DH domain binding to
the Rho GTPase switch region induces conformational remod-
eling of the nucleotide-binding pocket (44). Pleckstrin homology
(PH) domains are C-terminal adjacent associated regions to the
DH domain that regulate GEF activity (45). PH domains bind
phosphoinositides which facilitates plasma membrane localiza-
tion, although it has also been suggested that other domains are
necessary for directing subcellular localization (12). Furthermore,
there is evidence that GEFs may be negatively regulated by sites in
their N-terminus. The constitutive activation of many Rho GEFs
occurs following removal of N-terminal sequences with in vivo
protein expression (45); thus, the N-terminal region may act to
auto-inhibit the DH domain, the control of which can be relieved
by phosphorylation (12). Within the Dock family there are 11
members that are characterized by the presence of two conserved
domains, termed Dock-homology region-1 and -2 (DHR1 and
DHR2). For some Dock proteins, DHR2 has been shown to be
sufficient for catalytic activity (12, 46, 47). The mechanisms of
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signal activation, including GEF localization and protein interac-
tion, relief of auto-inhibition, and alteration of activity for Rho
GEFs remain poorly characterized.
DEREGULATION OF RhoGTPases IN GLIOMAS
Although Rac1-activating mutations are newly discovered and
described via exome sequencing in melanoma tissue (48, 49), to
date there are no reports of these mutations in other tumor types
including GB. Increased activity of Rac1 has been reported in GB,
and data supporting the role of additional Rho GTPases including
Cdc42, RhoG, and RhoA in GB progression have been detailed as
well, the findings of which are described below.
Rac
The levels of Rac1 protein correlate with tumor grade in astro-
cytomas. In GB, Rac1 prominent plasma membrane staining is
observed, indicating a potential hyper-activation status (50). Addi-
tionally, Rac1 promotes invasive glioma cell behavior (50, 51).
While most data supports the role of Rac1 in GB progression, the
Rac3 GTPase, which has high homology to Rac1, has also been
described to play a role in GB cell invasion; the siRNA-mediated
depletion of Rac3 led to strong inhibition of GB cell invasion
in vitro (52).
Rac1 facilitation of glioma cell invasion occurs via signaling
through several receptors and effectors. The tumor necrosis factor
receptor superfamily (TNFRSF) contains two members known to
utilize Rac1 in GB. Downstream of the fibroblast growth factor-
inducible 14 receptor (Fn14), the Rac1 protein is important in
promoting the TNF-like weak inducer of apoptosis (TWEAK)
ligand-induced activation of the Akt and NF-κB-pathways, and
Fn14 signaling through Rac1 promoted increased cell invasion
and resistance to cytotoxic therapy-induced apoptosis (51, 53,
54). Additionally, Fn14-induced Rac1 activation is mediated by
Cdc42. TWEAK-Fn14-induced Rac1 activation was dependent
upon the presence of Cdc42 protein, while Rac1 depletion had
no effect on TWEAK-induced Cdc42 activity (55). Moreover,
TWEAK-Fn14 signaling has been demonstrated to induce Rac1
activation through TNF receptor associated factor 2 (TRAF2)-
dependent activation of SGEF and RhoG (56). Another member
of the TNFRSF family, TROY, is overexpressed in glioma cells and
activates Rac1 signaling in a Pyk-2 dependent fashion, leading to
enhanced GB cell motility (57).
Rac1 activation and promotion of cell migration and invasion
in glioma is also seen downstream of signaling networks known
to be utilized in neuronal signaling and development. The neu-
ropeptide neurotensin induced activation of Rac1 in U373 GB
cells which express three subtypes of neurotensin receptors; neu-
rotensin enhances specifically the migration of cells cultured on
laminin, with neurotensin-treated cells migrating more slowly
when cultured on plastic (58). In addition, neuropilin-1 is a
receptor for the semaphorin family of axon guidance molecules,
and signaling through its ligand semaphorin3A promotes Rac1
activity and GB cell migration (59). Semaphorin 5A and its
receptor plexin-B3, however, have been shown to significantly
inhibit glioma cell migration and invasion, with concomitant
inactivation of Rac1 through RhoGDIα and the promotion of
glioma cell differentiation; semaphorin5A protein expression was
significantly reduced in high-grade astrocytomas (60, 61). The
axon guidance ligand Ephrin-B3 is overexpressed in GB cells
and expression correlates with invading cells, with Ephrin-B3
co-localizing with Rac1 at areas of lamellipodia formation (62).
The expression of Ephrin-B3 induced Rac1 activation in GB
cells (62).
Rac1 has also been shown to regulate the formation of
invadopodia, which are specialized formations of the plasma
membrane that promote degradation of the extracellular matrix,
an action critical in glioma cell invasion (52, 63). The depletion of
either Rac1 or synaptojanin 2, a Rac1 effector with phosphatidyli-
nositol phosphatase activity, decreases invadopodia formation,
and glioma cell invasion (64). Synaptojanin 2 is also enriched
in invadopodia (64). Additionally, Rac1 activation at the plasma
membrane in glioma is regulated by Geranylgeranyltransferase I
as well as RLIP76 modulation of ubiquitination (65, 66).
Rac1 signaling has also been reported to be activated down-
stream of several known receptor drivers of glioma malignancy.
For example, Rac1 was activated subsequent to EGFRvIII-Src
family kinase-dependent or protein kinase A-dependent phospho-
rylation of Dock180 (67, 68). Over half of “Classical” GB tumors, a
genetically defined GB subtype, contain either point or vIII EGFR
activating mutations (69), which results in a gain of function in-
frame deletion of the extracellular portion of the receptor protein
(70). Rac1 activation may be a key event in tumors of this sub-
type. Similarly, the PDGFRα receptor, which is amplified in a
significant proportion of gliomas (71), induced Src-dependent
Dock180 phosphorylation, with subsequent increased Rac1-GTP
activity and GB cell growth and invasion (72). Lastly, Rac1 acti-
vation has been described downstream of several other Ras or
Rho superfamily GTPases, including Rac1 activation subsequent
to IQ-domain GTPase-activating protein 1 (IQGAP1)-dependent
ADP-ribosylation factor 6 (ARF6) signaling (73). Rac1 activation
downstream of additional Rho GTPase family members in GB is
detailed below.
Cdc42 AND RhoG
There have been multiple described mechanisms of Rac1 acti-
vation in GB. Cdc42 and RhoG both share an overlapping set
of activators and effectors with Rac1, and have been shown to
function upstream of Rac1 in the regulation of several biological
functions, including cell polarity and cell migration (29, 30, 35,
74–77). In GB, there is data to support the activity of Cdc42 and
RhoG upstream of Rac1 activation; however the overall data on
the status of these GTPases in GB is limited. The TWEAK-Fn14
ligand receptor axis-induced activation of Rac1 is one mechanism
to enhance Rac1-GTP that is dependent upon a functional and
activated Cdc42 protein; the depletion of Cdc42 abrogated glioma
cell migration in vitro and invasion ex vivo (55). Cdc42 activation
has also been demonstrated alongside Rac1 activation in GB cells
downstream of PDGFRα association with SHP-2 non-receptor
protein tyrosine phosphatase and Dynamin 2 (Dyn2) to promote
glioma cell migration (78). The activation of Rac1 in neurotensin
neuropeptide treated glioma cells was described in parallel with
Cdc42 activity, although the dependence of one GTPase on the
other for activation was not explored (58). In addition, biosen-
sor studies have shown that both Cdc42 and Rac1 display high
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activity in the leading GB cells in the process of penetrating the
brain parenchyma (79).
RhoG protein levels are elevated in GB (77), and RhoG has
been reported to stimulate lamellipodia formation and confer
downstream activation of Rac1 with a subsequent increase in
cell migration (28–30, 77). Furthermore, TWEAK-Fn14 signal-
ing in GB induces the rapid activation of RhoG dependent upon
the receptor recruitment of TRAF2 and SGEF-mediated guanine
nucleotide exchange, leading to increased levels of active Rac1
(56). RhoG can also activate Rac1 and Cdc42 in the regulation
of neuronal process plasticity (80, 81), thus it remains a possibil-
ity that deregulated neuronal signaling and development pathways
may also utilize RhoG to promote glioma malignancy. In addition,
RhoG promoted caveolar endocytosis of growth factor receptors,
including the regulation of EGF receptor internalization (82, 83).
In GB, RhoG is activated downstream of EGF signaling and pro-
motes GB cell migration (77); RhoG, therefore, may play a yet
unidentified role in receptor trafficking within GB tumors.
There have also been several Rac1-independent functions of
Cdc42 and RhoG described in other signaling systems (31, 84–86),
although the data in GB is limited. Depletion of the Cdc42-specific
GAP ARHGAP21 altered GB cell morphology and increased Cdc42
activity, FAK phosphorylation, MMP-2 production, and the rate
of cell migration (87). Moreover, the Slit2 axon guidance mol-
ecule, which has been characterized to have lower expression in
primary glioma specimens and invasive glioma cells relative to
non-neoplastic brain, was described as part of the Slit2-Robo1
axis that inhibited glioma invasion through attenuation of Cdc42
activity (88). Evidence for RhoG regulation of GB cell invasion in a
Rac1-independent fashion has been demonstrated downstream of
HGF-induced invasion. RhoG depletion abolished HGF-induced
invasion, but only partially inhibited HGF-stimulated Rac1 activ-
ity (77), suggesting RhoG also can utilize Rac1-independent
mechanisms to promote HGF-induced cell motility.
RhoA
To date, much of the data on RhoA function in glioma remains
largely correlative. Decreased RhoA activity occurred in correla-
tion with increased glioma cell migration (51, 89–91). Functional
evidence for the role of RhoA has been demonstrated under the
inhibition of the RhoA effector ROCK, which led to activation
of Rac1 in glioma cells and promoted invasion. Of note, this
inhibition led to the cellular morphological changes including
an increase in the number and length of cell processes, increased
membrane ruffling, and collapse of actin stress fibers (92). In addi-
tion, the inhibition of Rho/ROCK downstream of LPA induced
glioma cell chemotaxis also led to cells that displayed long thin
morphologies with extension of processes (93). RhoA activation
in astrocytoma cells has been demonstrated to confer cell process
retraction and rounding in the presence of decreased Rac1 activ-
ity (94). Also, pharmacologic inhibition of Ras in GB resulted
in decreased Rac1 activity with coincident increased RhoA acti-
vation and stress fiber formation leading to rigid matrix attach-
ment and cell immobility (95). Similarly, pharmacologic EGFR
inhibition led to the Rho/ROCK-dependent formation of stress
fibers with consequent decreased glioma cell invasion (96). Addi-
tionally, treatment of GB cells with the plant growth modulator
Narciclasine led to increased ROCK activity and stress fiber forma-
tion, and resulted in increased survival of orthotopic xenograft-
bearing mice (97). One recent report links RhoA inhibition with
decreased mesenchymal type invasion, however the inhibitor uti-
lized also targets RhoB and RhoC, thus excluding a definitive
conclusion on the involvement of RhoA (98).
The RhoA and Rac1 pathways are increasingly associated with
the promotion of divergent modes of cell migration in other
systems; amoeboid type motility, characterized by cell rounding
has been demonstrated to be regulated by the Rho/ROCK path-
way, whereas prominent Rac signaling regulates mesenchymal type
invasion with long morphological process extension (99). These
modes of migration have been demonstrated to occur on differing
substrate rigidity and size (42). In GB there is insufficient func-
tional evidence for the role of RhoA in promoting amoeboid cell
migration.
It also is interesting to note that substrate preference in the
mode of GB cell invasion may be influenced by RhoA signaling.
FRET studies have shown that while activated Rac1 and Cdc42
was high in rat GB cells invading brain parenchyma, RhoA activity
was high in the perivascular region where there was coincident
lower activity of Rac1 and Cdc42 (79). Furthermore, the down-
stream Rho effector ROCK signaling has been demonstrated to be
an important modulator of substrate preference for GB cell route
of invasion into brain parenchyma (100).
ROLE OF GEFs IN GLIOMA
Of the more than 80 characterized Rho GEFs, the contribution
of GEFs to glioma pathobiology may be in large part due to their
expression patterns. Five of the GEFs described to promote GB
cell motility, including Ect2, Vav3, Trio, SGEF, and SWAP-70, are
overexpressed in GB versus non-neoplastic brain, and Dock180
expression is higher in the tumor rim than in the tumor core (50,
56, 76, 101).
Ect2, BETA-PIX, SWAP-70, SGEF
It is likely that tumor cell invasion depends on the specific intracel-
lular localization of Rho GEFs. Ect2, a GEF with RhoA, Cdc42, and
possible Rac1 activity, was initially shown to regulate cytokinesis
and actin cortex organization during mitosis (102, 103). While
low-grade astrocytomas show predominantly nuclear Ect2 stain-
ing; GBs display prominent Ect2 staining in both the cytoplasm
and nucleus (50,104). In GB cells,Ect2 confers exchange for Cdc42,
and subsequently Rac1, downstream of TWEAK-Fn14 (55). More-
over, Ect2 co-localizes with Rac1 and Cdc42 in the membrane
ruffles of migratory astrocytoma cells, and inhibition of Ect2 led
to decreased Rac1 and Cdc42 activity, with no change in Rho activ-
ity (104). Ect2 may additionally promote mesenchymal-amoeboid
transition via interaction with the Rho-GAP RASAL2 (104). Over-
expression of Ect2 in vivo promotes astrocyte migration in mice
(55). ARHGEF7 (βPIX), a GEF that acts on both Rac1 and Cdc42,
has additionally been studied in the context of cell migration (105).
In GB, βPIX has been shown to be recruited to the leading edge
of cell migration by the TIP-1 PDZ-scaffolding protein, where
co-localization with Rac1 and Cdc42 promotes cell motility (106).
The Rho GEF SWAP-70 was discovered as a primarily
nuclear protein with weak DNA-binding affinity in activated

























































Fortin Ensign et al. Rho GTPase signaling in glioma
B-lymphocytes (107). Recently, it has been shown to localize at
the leading edge of migrating glioma cells where it promoted
membrane ruffling and migration and invasion of glioma cells,
as well as the EGF-induced activation of Rac1 (101). In addi-
tion, the RhoG-specific exchange factor SGEF, which was ini-
tially characterized as an androgen-responsive gene in human
prostate cells, has been shown to induce membrane ruffling and
macropinocytosis in human fibroblasts (108, 109). SGEF localiza-
tion in non-transformed human keratinocytes was demonstrated
to be primarily nuclear, although HPV-mediated transformation
was shown to be dependent upon SGEF and RhoG cytoplasmic
activity, leading to increased membrane ruffling and cell invasion
(110). In GB, SGEF is overexpressed relative to non-neoplastic
brain tissue, and promotes the RhoG-mediated activation of Rac1
downstream of TWEAK-Fn14 signaling leading to increased cell
migration and invasion (56). Thus, the specific localization of
GEFs in brain tumors may promote cell invasion.
Vav
The Vav family of Rho GEFs has been shown to promote glioma
malignancy, however their isoform-specific roles vary among
tumor grade and cell type context dependence. Vav1 and Vav3
have independently been shown to be overexpressed in patients
with high-grade gliomas; Vav1, however, is overexpressed in per-
itumoral and perivascular, non-neoplastic astrocytes and thus its
role may be related to cross-talk between the microenvironment
and glioma cells. In contrast, Vav3 expression is localized to the
glioma cells and Vav3 was shown to mediate exchange for Rac1
in the promotion of glioma cell migration (50, 111). Vav2 has
been shown to exchange for Rac1 and promote chemotactic cell
migration via the G protein-coupled P2Y(2) nucleotide receptor
[P2Y(2)R] in low-grade astrocytomas, but has not been reported
to play a role in high-grade GB (112). Thus the Vav family of Rho
GEFs may promote malignancy across varying grades of brain
tumors.
TRIO
Trio is defined by a unique structure containing two active GEF
domains, one with Rac-specific activity and the second with Rho-
specific activity, as well as a protein serine/threonine kinase (PSK)
domain (113). Trio is overexpressed in high-grade gliomas and
correlates with poor patient outcome; the depletion of Trio inhibits
glioma cell invasion ex vivo (50, 55). Trio has been shown to confer
guanine nucleotide exchange for Rac1 downstream of TWEAK-
Fn14-induced Cdc42 activity, with subsequent promotion of cell
migration (55). The role of Trio exchange for RhoA has been unex-
plored in GB, however given that Rac1 and RhoA may regulate
divergent modes of invasion, it remains possible that Trio plays
a role in the regulation of mesenchymal-amoeboid shifts in the
migration of GB cells.
Dock
Within the Dock180 superfamily of proteins, Dock180 and Dock9
have been characterized in glioma. The Dock180 GEF signals as
a bipartite GEF for Rac1 in connection with the PH domain of
ELMO1, and expression of ELMO1 is elevated in a subset of GB
(47, 114). Furthermore, the exogenous expression of ELMO1 and
Dock180 in glioma cells enhances their migratory and invasive
capacities in vitro and in brain tissue (76). In addition, the phos-
phorylation of Dock180 at tyrosine 1811 has been demonstrated
to occur downstream of PDGFRα in glioma, promoting Rac1
activation and cell invasion, migration, and survival (72).
Dock9, also known as Zizimin1, is a Cdc42-specific Dock
family GEF. Dock9 interacts with the plasma membrane via its
N-terminal PH domain; the N-terminal region also serves to auto-
inhibit the catalytic function of Dock9 (115, 116). Dock9 was
initially characterized for its role in dendrite formation in rat
hippocampal neurons (117), but has recently been shown to be
important for GB cell invasion in the rat. GB cells with Zizimin1
knockdown displayed lower Rac1 and Cdc42 activity (79).
Roles for additional GEFs have yet to be defined in glioma,
but further characterization of GEF localization and activation
mechanisms may prove useful in understanding GB invasion.
GLIOMA PRO-INVASIVE PATHWAYS PROMOTE TUMOR
SURVIVAL
Cancer invasion and drug-resistance are increasingly being recog-
nized as interconnected processes sharing overlapping pathways
that together promote disease progression and therapy failure
(7). In GB, the tumor response to external stresses, including
from the tumor microenvironment or from chemotherapeutic or
radiation treatment, involves coordinated pro-survival and pro-
invasion signaling. The GB microenvironment is comprised of
areas of hypoxia notably including pseudopalisading necrosis, one
of the histological hallmarks of GB, which has been defined to
consist of tumor cells actively invading away from a hypoxic
core of tissue following a vaso-occlusive event. These hypoxia-
induced migratory cells have increased tumor cell glycolysis and
secrete pro-angiogenic factors (118–120), and increased microves-
sel density in astroglial brain tumors is a prognostic indicator
of poor patient survival (121). Thus, tumor hypoxia in GB pro-
motes both cell invasion into normal brain tissue and supports
angiogenesis for tumor survival and growth. Glioma cells with the
increased capacity for migration have a decreased expression of
pro-apoptotic genes and are less sensitive to cytotoxic therapy-
induced apoptosis (51, 53, 122–124). Several of the Rho GTPases
and Rho GEFs shown to promote GB cell invasion have also been
correlated to poor patient prognosis among GB tissue specimens
(50, 56, 72, 101), and signaling through Rho GTPases is part of the
coordinated survival response following treatment in GB.
For example, chemotherapeutic resistance in glioma cells has
been shown to be promoted through Rac1-dependent Akt2 activ-
ity working upstream of the BCL2 family to promote cell survival
(54). Activation of Akt2 led to increased MMP-9 expression and
increased glioma cell migration and invasion (125). The inhibi-
tion of NF-κB has been shown to promote increased glioma cell
death, which was synergistic under the combined treatment with
TMZ, and led to decreased migration and invasion with decreased
expression of invasion-related genes (126). Furthermore, overex-
pression of the pro-invasive TNFRSF member TROY increased
glioma cell resistance to irradiation or TMZ treatment depen-
dent upon Akt and NF-κB activity, and depletion of TROY in
orthotopically implanted primary GB xenografts led to increased
survival of mice (127). In addition, sub-optimal dosing of TMZ
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cooperatively reduces cell growth in EGFR inhibited glioma cells
with concomitant Rho/ROCK-dependent inhibition of glioma cell
invasion (96). Furthermore, glioma stem cells are increasingly
being recognized as TMZ resistant, both through intrinsic resis-
tance mechanisms and via interaction with the brain parenchyma
toward the promotion of extrinsic resistance (128). Rac1 has been
shown to be important for the maintenance of stemness and
tumorigenicity in human glioma, whereby depletion of Rac1 sup-
pressed glioma stem-like cell migration, invasion, and malignant
transformation, while conferring enhanced radiation sensitivity to
these glioma stem-like cells (129).
The irradiation of primary GB cells has been demonstrated
to enhance cell invasion (10). TRAF2, which has been shown to
be recruited upstream of SGEF-RhoG-Rac1 pro-invasive signal-
ing in the TWEAK-Fn14 axis (56), when depleted in GB has also
been shown to inhibit growth and confer radio-sensitization to
tumor cells (130). Additional reports have characterized that sig-
naling through TRAF2 promotes not only NF-κB activity, but also
JNK/SAPK activity, inflammation, and cell migration and chemo-
and radio-resistance of cancer cells (131–137). In GB, JNK is acti-
vated downstream of Rac1, whereby activated JNK translocated to
paxillin-containing focal complexes leading to paxillin phosphory-
lation at a site known to regulate cell migration (138). Moreover,
it has been suggested that Rac may promote radiation therapy-
induced increased glioma cell invasion in concert with activated
p38 and JNK signaling (139). In addition, the pharmacologic inhi-
bition of auto-phosphorylation of focal adhesion kinase in GB
was shown to inhibit cell invasion and increase cell apoptosis,
an effect which was synergistic when treated with TMZ in vivo
(140). Taken together, Rho GTPases and Rho GEFs are impli-
cated in the regulation of invasion and survival signaling in GB
(Figure 2).
FIGURE 2 | Rho GEF and Rho GTPase signaling in GB. Pro-invasive Rho
GEF family members Dock9, Vav2, Vav3, β-Pix, ELMO/Dock180, SWAP-70,
Ect2, Trio, and SGEF confer guanine nucleotide exchange for Rho GTPase
family members Rac1, Cdc42, and RhoG in glioma progression (Known GEFs
in glioma are summarized in insert with corresponding GTPases shown in
brackets; LGA, lower grade astrocytoma only). Cancer invasion and
drug-resistance share overlapping signaling pathways, including the signaling
through Rho GTPases in glioma. The inhibition of mediators of invasion
confers increased susceptibility to chemotherapeutic- and radiation-induced
cell death.
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CONCLUSION
Deregulated pathway signaling in GB tumors occurs within multi-
ple processes including proliferation, metabolism, gliomagenesis,
angiogenesis, survival, and invasion. Patient mortality is ultimately
due to tumor spread and growth burden, thus the identification
of key drivers of cell invasion can inform future targeted therapy
development for use in clinical trials, with the intent to sensi-
tize cells to combinatorial therapy with chemotherapeutic and
radiologic interventions.
The acquisition of cell motility is complex and influenced
by various intracellular and extracellular signaling events. The
Rho family of GTPases are well-defined regulators of actin
cytoskeletal dynamics (17, 24, 37), and have been characterized
to contribute to most steps of cancer initiation and progression
(141). Suppression of Rac activity selectively induces apopto-
sis in glioma cells but not in normal human astrocytes (142),
thus proffering a rationale for the therapeutic inhibition of
pro-migratory signaling pathways including those promoting
Rac activation as an effective clinical option for GB. Increased
support for the utility of Rho GTPase pathway inhibitors in
treating cancer has led to the recent development of several
strategies to identify drugs that will act against Rho GTPases,
or their regulation by GEFs (143–151). These studies high-
light the potential use of GEF inhibition and support both the
rationale for and the feasibility of future GEF inhibitors for
clinical use.
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